Botanix Pharmaceuticals Limited (AU:BOT) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Botanix Pharmaceuticals Limited, a clinical dermatology company, is set to host a webinar to discuss its market strategy and upcoming commercial launch of SofdraÔ, the first FDA-approved new chemical entity for treating primary axillary hyperhidrosis. The event will feature Botanix executives and notable guests from the International Hyperhidrosis Society, UpScript Health, and Klick Health. The webinar aims to offer insights into the treatment of this challenging medical condition and Botanix’s role in providing novel solutions.
For further insights into AU:BOT stock, check out TipRanks’ Stock Analysis page.